



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*February 25, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/511,922**

**FILING DATE: *October 16, 2003***

**RELATED PCT APPLICATION NUMBER: *PCT/US04/32305***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

ET 390094695 US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Jess G.		Thoene		New Orleans, LA	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
Treatments for Cancer					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number		<input type="text"/>		<input type="checkbox"/> Place Customer Number Bar Code Label here	
OR		Type Customer Number here			
<input checked="" type="checkbox"/> Firm or Individual Name		Tulane University			
Address		Office of Technology Development			
Address		1430 Tulane Avenue, SL13			
City		New Orleans		State	LA
Country		USA		ZIP	70112-2632
		Telephone	(504) 585-6962	Fax	(504) 584-2473
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages		<input type="checkbox"/> CD(s), Number	
		17			
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets		<input type="checkbox"/> Other (specify)	
		8			
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <input type="text"/>				\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

03917 U.S. PTO  
60/511922

101603

Respectfully submitted,

SIGNATURE

*J. Cale Lennon, III*

Date

10/16/2003

TYPED or PRINTED NAME J. Cale Lennon, III, Ph.D.

TELEPHONE (504) 585-6962

REGISTRATION NO.

(if appropriate)

Docket Number:

### USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

**Complete if Known**

Application Number	USPS Express ET 390094695 US
Filing Date	10/16/2003
First Named Inventor	Jess G. Thoene
Examiner Name	
Group Art Unit	
Attorney Docket No.	TM-254

TOTAL AMOUNT OF PAYMENT (\$ 80.00

**METHOD OF PAYMENT**

1. ☐ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:
- Deposit Account Number
- Deposit Account Name
- ☐ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
- ☒ Applicant claims small entity status. See 37 CFR 1.27
2. ☐ Payment Enclosed:
- ☒ Check ☐ Credit card ☐ Money Order ☐ Other

**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	
106 330	206 165	Design filing fee	
107 510	207 255	Plant filing fee	
108 740	208 370	Reissue filing fee	
114 160	214 80	Provisional filing fee	80.00

SUBTOTAL (1) (\$ 80.00

**2. EXTRA CLAIM FEES**

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** = <input type="text"/>	X <input type="text"/>	= <input type="text"/>
Multiple Dependent	-3** = <input type="text"/>	X <input type="text"/>	= <input type="text"/>

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 84	202 42	Independent claims in excess of 3
104 280	204 140	Multiple dependent claim, if not paid
109 84	209 42	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for ex parte reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
179 740	279 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify) 

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ **SUBMITTED BY**

Name (Print/Type) J. Cale Lennon, III, Ph.D.

Registration No.  
(Attorney/Agent)**Complete (if applicable)**

Telephone (504) 585-6962

Signature

Date 10/16/2003

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC

# **PROVISIONAL PATENT APPLICATION**

## **TITLE OF THE INVENTION**

**“TREATMENTS FOR CANCER”**

## **INVENTOR**

**Jess G. Thoene, a United States citizen, of New Orleans, Louisiana**

## **CROSS-REFERENCE TO RELATED APPLICATIONS**

**Not Applicable**

## **STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH**

**Not Applicable**

## **FIELD OF THE INVENTION**

**The present invention relates to compounds useful for the treatment of cancer.**

## BACKGROUND

Cancer is an abnormal growth of cells. In particular, this abnormal growth is unresponsive to normal physiological restraints on cell growth. In some cases the production or growth of cells is warranted and necessary. In some cases, new cell growth is mandated by the death of existing cells. The death of cells can be random, caused by a myriad of conditions such as lack of nutrients, cellular damage, infection or exposure to toxins. However, in some cases the death of cells follows a controlled program. This phenomenon is known as apoptosis. Apoptosis is also known as planned cell death or controlled cell death. The death of cells by apoptosis differs in many respects from the death of cells by other means. Cells that die as a result of apoptosis exhibit hallmark molecular and physiological features that are distinct from those of cells that die as a result of necrosis (Kanduc *et al.*, 2002). The process of apoptosis is characterized by several molecular features. One is the production of enzymes that causes cleavage of intracellular DNA that can be seen as a laddering pattern following gel electrophoresis (Shiokawa *et al.*, 2002). Apoptosis is also characterized by zeiosis or blebbing of cell nuclei (Coleman *et al.*, 2001). These features contrast with those associated with cell death by necrosis, which show no systematic breakdown of DNA and is usually accompanied by inflammation (Sauter *et al.*, 2000). Apoptosis has proven to be an intriguing option for those seeking additional methods of treating cancer because it is considered to be a more gentle treatment and likely to result in less unwanted damage to otherwise healthy cells.

Current treatments for cancer are centered on chemotherapeutic agents and radiation therapy. The goal of these two regimens is usually considered to be the killing of rapidly dividing cells by interfering with processes involved in the replication of cells. These treatments exploit the susceptibility of dividing cells to certain agents. Some of these methods include

treatments designed to damage microtubule assembly during mitosis such as colchicine and paclitaxel (Kaufmann and Earnshaw, 2000). There are other chemotherapeutic drugs that interfere with the replication of DNA such as doxorubicin and epirubicin (Buschini *et al.*, 2003). While these therapies are targeted to cancerous cells, they have similar effects on otherwise healthy cells involved in the cell division process. Therefore there is a need to develop alternate treatments for cancer that pose less of a danger to otherwise healthy cells.

Current examples of compounds that are used to treat cancer are usually considered to be effective due to their ability to interfere with the processes involved with cell division. However, there is growing evidence that some of these molecules are also able to induce apoptosis in the cancer and otherwise healthy cells (Kaufmann and Earnshaw, 2000). Researchers have been able to observe some of the characteristic features of apoptosis in cells subjected to currently used chemotherapeutic drugs. Many of the compounds used to treat cancer are also toxic to otherwise healthy cells. This is also true of some of the compounds used to induce apoptosis. The development of methods of treatment that utilize apoptosis as a treatment for cancer present a threat to otherwise healthy cells. Therefore methods of reducing the amount of an agent needed to induce apoptosis would be of great therapeutic benefit in the development of apoptotic cancer therapeutics.

Some of the molecules currently used to induce apoptosis are tumor necrosis factor alpha, ultraviolet light and Fas antibodies. These agents are routinely used to induce apoptosis in laboratory models of cancer. Several of the agents have limited suitability as possible treatment agents in individuals because of the physical nature of the treatment. For example ultraviolet light has only a limited ability to penetrate cells or the tissues of an individual. Some agents such as tumor necrosis factor alpha are peptides that require expensive synthesis and would

prove costly as treatments for individuals. Because of these limitations, any treatments that are able to enhance the apoptotic effect of known inducers of apoptosis or chemotherapeutic agents would be beneficial.

## **SUMMARY OF THE INVENTION**

The present invention relates to novel compositions and methods for the treatment of various types of cancers. In one aspect of the invention, the invention involves compounds having the formula  $[\text{CH}_3\text{OR}_1-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue.

In another aspect of the invention, the invention involves compounds having the formula  $[\text{CH}_3\text{OR}_1-\text{R}_2-\text{R}_3 \dots \text{R}_n-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and  $\text{R}_2 \text{ R}_3 \dots \text{R}_n$  are amino acid residues.

In another aspect of the invention the invention involves a method of treating cancer by administering to a patient a compound having the formula  $[\text{CH}_3\text{OR}_1-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue.

In a further aspect of the invention, the invention involves a method of treating cancer in by administering to a patient a compound having the formula  $[\text{CH}_3\text{OR}_1-\text{R}_2-\text{R}_3 \dots \text{R}_n-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and  $\text{R}_2 \text{ R}_3 \dots \text{R}_n$  are amino acid residues.

In another aspect of the invention, the invention involves a method of treating cancer by administering to patient a compound having the formula  $[\text{CH}_3\text{OR}_1-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and



where said compound is administered in conjunction with or prior to the administration of a chemotherapeutic agent.

In another aspect of the invention, the invention involves a method of treating cancer by administering to patient a compound having the formula  $[\text{CH}_3\text{OR}_1-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and where said compound is administered in conjunction with or prior to the administration of a chemotherapeutic agent, said chemotherapeutic agent being an inducer of apoptosis.

In a further aspect of the invention, the invention involves a method of treating cancer by administering to a patient a compound having the formula  $[\text{CH}_3\text{OR}_1-\text{R}_2-\text{R}_3 \dots \text{R}_n-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and  $\text{R}_2 \text{ R}_3 \dots \text{R}_n$  are amino acid residues and where said compound is administered in conjunction with or prior to the administration of chemotherapeutic agent.

In a further aspect of the invention, the invention involves a method of treating cancer by administering to a patient a compound having the formula  $[\text{CH}_3\text{OR}_1-\text{R}_2-\text{R}_3 \dots \text{R}_n-\text{NH}_2-\text{CO}-\text{NH}-\text{CH}_2-\text{CH}_2-\text{S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and  $\text{R}_2 \text{ R}_3 \dots \text{R}_n$  are amino acid residues and where said compound is administered in conjunction with or prior to the administration of chemotherapeutic agent, said chemotherapeutic agent being an inducer of apoptosis.

In another aspect of the invention, the invention involves a method of treating cancer by administering to a patient the compound cystine dimethyl ester.

In another aspect of the invention, the invention involves a method of treating cancer by administering to a patient the compound cystine dimethyl ester in conjunction with or prior to the administration of a chemotherapeutic agent.



In another aspect of the invention, the invention involves a method of treating cancer by administering to a patient the compound cystine dimethyl ester in conjunction with or prior to the administration of a chemotherapeutic agent, said chemotherapeutic agent being an inducer of apoptosis.

## **DETAILED DESCRIPTION OF THE INVENTION**

The present invention involves compounds and methods for treating cancer. In accordance with the present invention, cysteine dimethyl ester (CDME) is administered to a patient diagnosed with cancer as part of a therapeutic regimen that includes one or more chemotherapeutic agents. As a preferred embodiment, the chemotherapeutic agent is a compound that induces apoptosis. In another preferred embodiment, the cancer is an epithelial-derived cancer. Examples of epithelial derived cancers include renal cell carcinoma and pancreatic cancer.

Another aspect of the present invention involves novel compounds having the formula  $[\text{CH}_3\text{OR}_1\text{-R}_2\text{-R}_3 \dots \text{R}_n\text{-NH}_2\text{-CO-NH-CH}_2\text{-CH}_2\text{-S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and  $\text{R}_2 \text{ R}_3 \dots \text{R}_n$  are amino acid residues. As a preferred embodiment, the compound has the formula  $[\text{CH}_3\text{OR}_1\text{-NH}_2\text{-CO-NH-CH}_2\text{-CH}_2\text{-S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from either an aspartate or glutamate amino acid residue. As an example, the compound aspartyl-cystamine disulfide is shown in Figure 7.

Another aspect of the present invention involves administering a compound having the formula  $[\text{CH}_3\text{OR}_1\text{-R}_2\text{-R}_3 \dots \text{R}_n\text{-NH}_2\text{-CO-NH-CH}_2\text{-CH}_2\text{-S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from an aspartate or glutamate amino acid residue and  $\text{R}_2 \text{ R}_3 \dots \text{R}_n$  are amino acid residues, to a patient diagnosed with cancer as part of a therapeutic regimen that includes one or

more chemotherapeutic agents. As a preferred embodiment, the compound has the  $[\text{CH}_3\text{OR}_1 - \text{NH}_2\text{-CO-NH-CH}_2\text{-CH}_2\text{-S}]_2$  where  $\text{CH}_3\text{OR}_1$  is a terminal ester derived from either an aspartate or glutamate amino acid residue. As further a preferred embodiment, the chemotherapeutic agent is a compound that induces apoptosis. In another preferred embodiment, the cancer is an epithelial-derived cancer.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1.** The effect of MEA or cystine dimethylester (CDME) on apoptosis in semi-confluent nephropathic cystinotic or normal fibroblasts. Apoptosis was assayed by CaspACE.

Nephropathic cystinotic fibroblasts (passage 7–13) were treated with cysteamine 1 hour before exposure to apoptotic triggers, depleting them to a normal lysosomal cystine content (0.01 to 0.13 nmol of cystine per mg of protein). Normal fibroblasts also at passage 7–13 were pretreated with 0.5mM CDME for 1 hour before apoptotic triggers, loading their lysosomes with cystine to the cystinotic range (0.47 to 1.95 nmol of cystine per mg of protein). They were then treated with apoptotic stimuli and incubated for 16 hours while in cystine-free or CDME-containing medium. Apoptosis was assayed by CaspACE.

**Figure 2.** (A through D) The effect of lysosomal cystine in normal and nephropathic cystinotic fibroblasts. Nephropathic cystinotic fibroblasts were exposed to UV light (60 mJ) (A) or pretreated with 1.0 mM MEA for 1 h and then exposed to UV light (60 mJ) (B). Normal fibroblasts were exposed to UV light (60 mJ) (C) or pretreated with 0.5 mM CDME for 1 hour and then exposed to UV light (60 mJ) (D). Apoptosis was then assessed by CaspACE and photographed by fluorescent microscopy. The cystine content of parallel plates was as follows:

A, 4.0 nmol/mg protein; B, 0.01 nmol/mg protein; C, <0.01 nmol/mg protein; D, 1.95 nmol/mg protein.

**Figure 3.** The effect of CDME or MEA on the morphology of normal or nephropathic cystinotic fibroblasts. Fibroblasts were cultured under the usual conditions and exposed to TNF- $\alpha$  for 16 hours as described in Materials and Methods. Panels a through c are normal fibroblasts; panels d through f are nephropathic cystinotic fibroblasts. Panels b and e show cells after TNF- $\alpha$  exposure alone; panels c and f show the effect of CDME in normal cells (c) or MEA in cystinotic cells (f). Note typical apoptotic morphology in panels b, c, and e, with more apoptotic cells in e (cystinotic) than b (normal). Enhanced apoptosis is seen in normal cells to which CDME is added (c). More normal morphology is seen in nephropathic cystinotic cells after MEA treatment (f). Photographs via phase microscopy.

**Figure 4.** Loss of colocalization of cathepsin B in normal and nephropathic cystinotic fibroblasts after TNF- $\alpha$  exposure. Fibroblasts were maintained under normal culture conditions, exposed to TNF- $\alpha$ , loaded with LysoTracker red, fixed, and stained for cathepsin B using an anti-cathepsin B antibody as described in Materials and Methods. Panels a through f are normal fibroblasts; a through c are control cells; d through f are treated with TNF- $\alpha$ . Panels g through l are cystinotic fibroblasts; g through i are control; j through l are treated with TNF- $\alpha$ .

**Figure 5.** The effect of CDME on apoptosis in renal proximal tubule epithelial (RPTE) cells. Semi-confluent RPTE cells were treated with either 0.25 mM CDME or TNF- $\alpha$ , harvested at 0.5, 1, 3, and 6 hours, stained with TUNEL, and enumerated by fluorescence microscopy.

**Figure 6.** The effect of CDME on apoptosis in RPTE cells. Fluorescent micrographs of the cells in Figure 5 are shown at 0.5, 1, 3, and 6 hours (A through D, respectively).

**Figure 7.** Aspartyl-cystamine disulfide.

**Figure 8.** Effect of Various Compounds on Rate of Apoptosis.

## **EXAMPLES**

### **Cystine Binding Protein Assay**

Intracellular lysosomal free cystine was determined using a cystine binding protein (CBP) assay as described. CBP was procured from Riverside Scientific. The assay has a sensitivity of 0.1  $\mu$ M. Total cell protein was determined by a modification of the Lowry method. Statistical analyses were performed using paired *t* test for means with SSPS for Windows.

### **Immunohistochemistry of Normal and Cystinotic Fibroblasts**

Cells were stained with LysoTracker Red (Molecular Probes) for 5 min at room temperature, washed twice in PBS, and then fixed in 4% formalin for 1 hour. Slides were immersed in blocking buffer (PBS, pH 7.2, 0.5% Carnation dry milk, 0.1% Triton X-100) for 20 min at room temperature, washed twice in PBS, and then incubated with primary antibody (anti-cathepsin B, Santa Cruz Biotechnologies) diluted 1:100 for 2 hours at room temperature, followed by incubation with secondary antibody (FITC-conjugated rabbit anti-goat, Santa Cruz Biotechnologies), at 4°C overnight. Slides were washed twice with PBS and then sealed with cover slips and viewed using a Leica DMRX deconvoluting microscope.



### Effect of Various Compounds on Rate of Apoptosis

Cells were incubated with various apoptotic compounds at a concentration of 0.5 mM for 16 hours. The structures of the treatment compounds are shown in Figure 8. Following incubation, cells were stained with CaspASE. Fluorescence-activated cell sorting (Beckman Coulter Epics Elite) was used to determine the percentage of cells undergoing apoptosis from each treatment group.

### Cell Culture

Normal and cystinotic fibroblasts were purchased from The Coriell Mutant Cell Repository, and cultured in Coon modification of Ham F12 medium, supplemented with 10% fetal calf serum (FCS). Renal proximal tubule epithelial (RPTE) cells were purchased from Biowhittaker, cultured in renal epithelial basal medium supplemented with one Singlequots kit per 500 ml to make renal epithelial growth media (REGM, Biowhittaker). Fibroblasts and RPTE were maintained in a 5% carbon dioxide, 95% air, humidified incubator at 37°C. Induction of apoptosis and assays for its detection were performed using commercially available reagents. Normal and cystinotic fibroblasts were matched for passage number and cell density, and then exposed to one of three apoptotic triggers: TNF- $\alpha$  (2 ng/ml) with actinomycin D (2.5  $\mu$ g/ml) for 16 h; anti-Fas antibody (500 ng/ml) with actinomycin D (2.5  $\mu$ g /ml) for 16 h; or UVB light (60 mJ). After exposure, the cells were maintained in Coon modification of Ham F12 medium for 16 hours before analysis. The cells were then assayed for apoptosis. Serum withdrawal was also used as an apoptotic stimulus, in which case the cells were incubated in F12 medium without serum for 24 hours and then analyzed for apoptosis as described. Three commercially available

apoptosis assays were employed. CaspACE (Promega) is an FITC-conjugated cell-permeable form of the pan-caspase inhibitor zVAD-Fmk, which binds to activated caspase(s).

Cells were incubated in FITC-VAD-Fmk-containing medium (10  $\mu$ M for 30 minutes at 37°C), washed, and then fixed in 10% buffered formalin (30 minutes at room temperature) before analysis. TUNEL employs terminal deoxynucleotidyl transferase (TdT) to label the ends of double-stranded DNA breaks, which occur in apoptotic cells, with FITC-conjugated dUTP. Cells were fixed in 4% buffered formalin, washed, incubated in permeabilization solution (0.1% Triton X-100 in 0.1% Na Citrate) for 2 minutes on ice and then stained with 25  $\mu$ l of TdT/45  $\mu$ l of labeled dNTP mix for 40 min at 37°C. Annexin V-propidium iodide (PI) staining was performed as described (Annexin V Fluos kit directions, Roche Laboratories). The cells were visually enumerated by fluorescence microscopy, scoring a minimum of five fields (250 to 300 cells) for fluorescence in triplicate followed by counting all cells in the same field by light microscopy, with a minimum of 750 cells scored per condition. The apoptosis rate is the total number of cells that fluoresce divided by the total cells in the field.

Lysosomal cystine depletion of cystinotic fibroblasts was accomplished by treatment with 1 mM cysteamine-HCl(Sigma) in Ham F12 medium lacking cystine (Life Technologies), with 10% FCS, for 1 hour followed by exposure to the apoptotic triggers in cystine-free medium to inhibit cystine re-accumulation. Normal fibroblast lysosomes were loaded with cystine by the addition of 0.5 mM cystine dimethylester (CDME, Sigma) to normal culture medium for 1 hour before treatment. The cells were treated with apoptotic triggers as described above, leaving CDME in the medium to prevent lysosomal cystine loss, and then analyzed for apoptosis as described. Lysosomal cystine loading of RPTE cells was accomplished by exposure to 0.1 mM or 0.25 CDME in normal REGM for 1 hour before treatment with or without apoptotic triggers.

## Results

The cell lines studied, their genotypes, and nominal cystine content are listed in Table 1. The mutations in cell lines GM00008, GM00760, and GM00046 cause typically severe nephropathic cystinosis with ESRD by 10 yr of age. The cystine content shown in the cystinotic lines in Table 1 varies between 0.8 and 15.7 nmol/mg protein, which is that typically seen in cultured cystinotic fibroblasts. Apoptosis induced in three nephropathic cystinotic, two normal, one intermediate cystinotic, and one ocular cystinotic fibroblast line by three separate inducers is shown in Tables 2 and 3. In Table 2, apoptosis in these lines was assessed by CaspACE. The cystinotic cells on average display about 2 to 3 times the apoptotic rate for the three apoptotic triggers compared with the normal cell lines. The cystinosis variant lines do not show increased apoptosis under these conditions. The differences are statistically significant at  $P \pm 0.05$  between the averages for cystinotic and normal lines and between nephropathic and ocular cystinotic lines. There is no significant difference in the rate of apoptosis between intermediate and nephropathic lines, ocular cells and normal cells, or intermediate *versus* normal cells (Table 2). Similar results were obtained when the cells were analyzed by TUNEL, except that line GM00008 did not differ significantly from the normal lines' response after anti-Fas or UV exposure, nor did line GM00046 after TNF- $\alpha$  exposure (Table 3). Again, the variant lines did not show augmented apoptosis compared with the normal fibroblast lines.

**Table 1.** Genotype and cystine content of cell lines

Cell Line	Phenotype	Genotype	Cystine Content (nmol/mg protein)
GM00008	Nephropathic	46XX, 65-kb del	7.5
GM00760	Nephropathic	46XY, 753 G3A, premature stop	0.78
GM00046	Nephropathic	46XY, 5-bp del, frameshift	1.51
GM08761	Ocular	46XX, not determined	6.29
GM00379	Intermediate	IVS11_2 T3C	15.7
GM00010	Normal	46XY, apparently normal	0.01
GM05399	Normal	46XY, apparently normal	0.01
RPTE	Normal	46XY, apparently normal	0.6

**Table 2.** The apoptosis rate in cystinotic nephropathic, variant, and normal fibroblasts

		% Apoptosis			
		TNF- $\alpha$	Anti-Fas	UV	Control
GM008	Nephropathic	14.9	17.7	12.8	2.2
GM760	Nephropathic	13.5	14.4	26.3	3.1
GM046	Nephropathic	16.1	22.3	13.1	2.2
Average		14.8	18.1	17.4	2.5
GM08761	Ocular	8.2	5.9	6.4	2.3
GM00379	Intermediate	11.4	7.7	8.4	3.1
GM010	Normal	9.2	6.5	7.0	2.8
GM05399	Normal	6.3	4.9	7.2	1.9
Average		7.8	5.2	7.1	2.4

**Table 3.** The apoptosis rate in normal and cystinotic fibroblasts cell

		%Apoptosis			
	Phenotype	TNF- $\alpha$	Anti-Fas	UV	Control
GM00008	Nephropathic	17.1	12.3	13.7	3.1
GM00760	Nephropathic	19.3	17.7	21.6	2.4
GM00046	Nephropathic	15.3	15.9	19.2	2.6
Average	Nephropathic	17.2	15.3	18.2	2.7
GM08761	Ocular	5.5	7.1	6.8	3.4
GM00379	Intermediate	8.2	8.5	8.5	2.8
GM00010	Normal	12.8	9.6	11.9	2.4
GM05399	Normal	11.4	10.5	7.6	2.4
Average	Normal	12.1	10.1	9.8	2.4

Modulation of the apoptotic response by altering the lysosomal cystine content of normal or nephropathic cystinotic fibroblasts is shown in Figure 1. The bar graphs show the apoptosis rates induced by exposure of two cystinotic and two normal cell line cells to TNF- $\alpha$  or UV radiation before and after correction of the cystine content of nephropathic fibroblasts to normal levels with MEA and before and after increasing the cystine content of normal fibroblasts to cystinotic levels by pre-incubation with CDME. The mean rate of apoptosis for the cystinotic cells before cystine depletion was 15.6  $\pm$  2.7%; after cystine depletion by exposure to MEA, it fell to 6. This difference is significant at  $P < 0.001$ . The average control apoptotic rate for the normal fibroblast lines was 7.2  $\pm$  1.3%, which rose to 18.7  $\pm$  5.4% after exposure to CDME ( $P < .001$ ). The effect holds whether induction was by TNF- $\alpha$  or UV light. Representative fluorescence micrographs displaying this effect after UV exposure are shown in Figure 2. The



high rate of apoptosis in cystinotic fibroblasts with initial cystine content of 4.0 nmol/mg protein is shown in Figure 2A. This fell after treatment with cysteamine, which lowered the cystine content to < 0.1 nmol/mg protein (Figure 2B). The normal rate of apoptosis in normal fibroblasts (cystine content <0.1 nmol/mg protein) is shown in Figure 2C, and this increases to a rate similar to that seen in cystinotic fibroblasts after pre-exposure of the cells to CDME (Figure 2D), which increased the cystine content to 1.95 nmol/mg protein. Representative phase micrographs of fibroblasts treated with TNF- $\alpha$ , showing characteristic apoptotic morphology, and the effect of lysosomal cystine on apoptosis are shown in Figure 3, in which typical blebs in the plasma membrane are seen after treatment with TNF- $\alpha$  in both normal and cystinotic cell lines and the modulating effects of MEA and CDME on apoptosis are seen. Serum withdrawal in cultured fibroblasts caused less apoptosis above baseline than the other stimuli employed; however, increasing lysosomal cystine, either naturally due to defective CTNS function or artificially due to CDME loading, again resulted in an increased apoptotic rate (Table 4).

**Table 4.** Apoptosis in normal and nephropathic cystinotic fibroblasts exposed to serum withdrawal

Condition	%Apoptosis	
	GM00008	GM05399
Untreated controls	2.8	3.1
Serum withdrawal	8.7	6.1
Serum withdrawal and MEA	7.2	--
Serum withdrawal and CDME	--	37.3

To substantiate that lysosomes are permeabilized by TNF- $\alpha$  under these conditions, cathepsin B (a lysosomal cysteine protease) was localized by immunohistochemistry in normal and nephropathic cystinotic cells before and after induction of apoptosis. Lysosomes were identified with Lysotracker red dye. In both normal and cystinotic fibroblasts before TNF- $\alpha$  treatment, cathepsin B (green) displays a punctuate pattern that is closely associated with the red

lysosomal dye. Induction of apoptosis by TNF- $\alpha$  causes a translocation of cathepsin B from a lysosomal location to a diffuse cytosolic location, with loss of co-localization of color (Figure 4).

Cultured human renal proximal tubule epithelial cells display marked sensitivity to apoptosis after CDME exposure (Table 5). The concentration employed in fibroblasts (0.5 mM) was toxic to these cells and was decreased to 0.1 or 0.25 mM for the RPTE experiments. The rate of apoptosis produced by 0.25 mM CDME alone was equal to that induced by exposure to TNF- $\alpha$  alone (Figure 5). The time course was accelerated, with these cells attaining a maximum rate of apoptosis within 6 hours, (as opposed to 17 hours in fibroblasts) followed by lysis and release from the culture dish. The RPTE cystine content after exposure to 0.25 mM CDME for 1 hour was 1.99 nmol/mg protein. Representative fluorescence micrographs at each time point are shown in Figure 6.

**Table 5.** Percentage of apoptosis induced by selected compounds

<u>Compound</u>	<u>% Apoptosis</u>
Control	5.3
Cystine	8.3
CDME	39.7
Cystamine	5.0
Djenkolic Acid	5.8
DKADME	6.0
Penicillimine disulfide	4.5
PDDME	5.8
Cys-ala disulfide	5.1
CADME	4.8
Cys-gly disulfide	4.4
CGDME	7.4
Cys-val disulfide	6.3
CVDME	4.5

## REFERENCES

1. D. Kanduc, A. Mittelman, R. Serpico, E. Sinigaglia, A.A. Sinha, C. Natale, R. Santacroce, M.G. Di Corcia, A. Lucchese, L. Dini, P. Pani, S. Santacroce, S. Simone, R. Bucci and E. Farber. Cell death: Apoptosis versus necrosis (Review). *International Journal of Oncology*. July 2002 v21 pages 165-170
2. D. Shiokawa, T. Kobayashi, S. Tanuma. Involvement of DNase in Apoptosis with Myogenic Differentiation of C2C12 Cells. *Journal of Biological Chemistry*. August 23, 2002 v277 no 34 pages 31031-31037
3. M. Coleman, E. Sahai, M. Yeo, M Bosch, A. Dewar, M. Olson. Membrane Blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nature Cell Biology*. April 2001 v3 issue 4 pages 339-345
4. B. Sauter, M. Albert, L. Francisco, M. Larson, S. Somersan, N. Bhardwaj. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. *Journal of Experimental Medicine*. February 7, 2002 v191 pages 423-433
5. S. Kaufmann, W. Earnshaw. Induction of Apoptosis by Cancer Chemotherapy. *Experimental Cell Research*. April 10, 2000 v256 pages 42-49
6. A. Buschini, P.Poli, C. Rossi. *Saccharomyces cerevisiae* as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones. *Mutagenesis*. January 2003 v18 no 1 pages 25-36

## **CLAIMS**

I claim:

1. A method of treating cancer consisting of administering to a patient cystine dimethyl ester, and a pharmaceutically acceptable carrier.






FIGURE 1





FIGURE 2



**FIGURE 3**




FIGURE 4






FIGURE 5





FIGURE 6



**FIGURE 7**














Structure	Treatment	% Apoptosis
	Control	5.3
	Cystine	8.3
	CDME	39.7
	Cystamine	5.0
	Djenkolic Acid	5.8
	DKADME	6.0
	Penicillimine disulfide	4.5
	PDDME	5.8
	Cys-ala disulfide	5.1
	CADME	4.8
	Cys-gly disulfide	4.4
	CGDME	7.4
	Cys-val disulfide	6.3
	CVDME	4.5

FIGURE 8

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/032305

International filing date: 15 October 2004 (15.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/511,922  
Filing date: 16 October 2003 (16.10.2003)

Date of receipt at the International Bureau: 07 March 2005 (07.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse